Phase 3 RCT in 2713 adults with type 2 diabetes and BMI ≥25 on metformin: cagrilintide-semaglutide (2.4 mg each) vs semaglutide 2.4 mg reduced HbA1c more at 68 weeks (-1.91 vs -1.75 points; difference -0.16). Adverse events 86.9% vs 81.2%.
RCTn = 2,713
Buse et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study